These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35032505)

  • 1. Zuranolone provides a rapid response without chronic dosing: Response to correspondence by ten Doesschate et al.
    Arnaud A; Bonthapally V
    J Affect Disord; 2022 Mar; 301():445-447. PubMed ID: 35032505
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
    Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
    J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
    Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.
    Meshkat S; Teopiz KM; Di Vincenzo JD; Bailey JB; Rosenblat JD; Ho RC; Rhee TG; Ceban F; Kwan ATH; Cao B; McIntyre RS
    J Affect Disord; 2023 Nov; 340():893-898. PubMed ID: 37557991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zuranolone: First Approval.
    Heo YA
    Drugs; 2023 Nov; 83(16):1559-1567. PubMed ID: 37882942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zuranolone Treatment for Depression: Steady Progress in Mechanism-Focused Therapeutics?
    Pine DS
    Am J Psychiatry; 2023 Sep; 180(9):631-633. PubMed ID: 37654113
    [No Abstract]   [Full Text] [Related]  

  • 7. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
    Arnaud A; Suthoff E; Stenson K; Werneburg B; Hodgkins P; Bonthapally V; Jonas J; Meyer K; O'Day K
    J Affect Disord; 2021 Apr; 285():112-119. PubMed ID: 33640861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New depression drug zuranolone one step closer to FDA ruling.
    Carvalho T
    Nat Med; 2023 May; 29(5):1032-1033. PubMed ID: 37041352
    [No Abstract]   [Full Text] [Related]  

  • 9. Still no evidence for the efficacy of zuranolone beyond two weeks: Response to Arnaud and Bonthapally.
    Ten Doesschate F; van Waarde JA; van Wingen GA
    J Affect Disord; 2022 Sep; 313():149-150. PubMed ID: 35780962
    [No Abstract]   [Full Text] [Related]  

  • 10. Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study.
    Bullock A; Kaul I; Li S; Silber C; Doherty J; Kanes SJ
    J Neurol Sci; 2021 Feb; 421():117277. PubMed ID: 33387701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults.
    Bullock A; Gunduz-Bruce H; Zammit GK; Qin M; Li H; Sankoh AJ; Silber C; Kanes SJ; Jonas J; Doherty J
    Hum Psychopharmacol; 2022 Jan; 37(1):e2806. PubMed ID: 34352138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-superiority of zuranolone (SAGE-217) at the longer-term.
    Ten Doesschate F; van Waarde JA; van Wingen GA
    J Affect Disord; 2021 Aug; 291():329-330. PubMed ID: 34082218
    [No Abstract]   [Full Text] [Related]  

  • 13. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concerns That May Limit the Utility of Zuranolone.
    Prasad V; Allely D
    JAMA; 2024 Jan; 331(2):105-106. PubMed ID: 38100400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.
    Cerbo AD
    Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders.
    Eser D; Schüle C; Romeo E; Baghai TC; di Michele F; Pasini A; Zwanzger P; Padberg F; Rupprecht R
    Psychopharmacology (Berl); 2006 Jun; 186(3):373-87. PubMed ID: 16247651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroactive steroids - new possibilities in the treatment of postpartum depression.
    Žigová L; Massarová P; Vranecová K; Hrubá O; Adamičková A; Gažová A
    Ceska Slov Farm; 2022; 71(4):142-150. PubMed ID: 36208918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of SAGE-217 in Patients with Major Depressive Disorder.
    Gunduz-Bruce H; Silber C; Kaul I; Rothschild AJ; Riesenberg R; Sankoh AJ; Li H; Lasser R; Zorumski CF; Rubinow DR; Paul SM; Jonas J; Doherty JJ; Kanes SJ
    N Engl J Med; 2019 Sep; 381(10):903-911. PubMed ID: 31483961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of neuroactive steroids for the treatment of postpartum depression.
    Gunduz-Bruce H; Takahashi K; Huang MY
    J Neuroendocrinol; 2022 Feb; 34(2):e13019. PubMed ID: 34462985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Oral Drug Rapidly Treats Postpartum Depression.
    Slomski A
    JAMA; 2021 Sep; 326(9):800. PubMed ID: 34547091
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.